Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 5, 2014, Pages 1028-1034

  Seto, Wai Kay ^a   Lam, Yuk Fai ^a   Fung, James ^a,b   Wong, Danny Ka Ho ^a,b   Huang, Fung Yu ^a   Hung, Ivan Fan Ngai ^a   Lai, Ching Lung ^a,b   Yuen, Man Fung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Entecavir; ETV; HBsAg; Nucleoside analogue; Surface antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHINESE; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROCONVERSION; SEROLOGY; SUBARACHNOID HEMORRHAGE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PREGNANCY; TIME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREGNANCY; TIME FACTORS; YOUNG ADULT;

EID: 84898888815     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12476     Document Type: Article

References (31)

1. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
2. Yuen MF, Seto WK, Chow DH etal. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther. 2007; 12: 1295-1303.
3. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-1020.
4. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am. J. Gastroenterol. 2011; 106: 1264-1271.
5. Chang TT, Lai CL, Kew Yoon S etal. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
6. Chang TT, Liaw YF, Wu SS etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
7. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
8. Brunetto MR, Oliveri F, Colombatto P etal. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
9. Tseng TC, Liu CJ, Yang HC etal. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1149.
10. Seto WK, Wong DK, Fung J etal. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS ONE 2012; 7: e43087.
11. Seto WK, Wong DK, Fung J etal. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012; 56: 812-819.
12. Moucari R, Mackiewicz V, Lada O etal. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
13. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J. Infect. Dis. 2011; 204: 415-418.
14. Fung J, Lai CL, Young J etal. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am. J. Gastroenterol. 2011; 106: 1766-1773.
15. Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-931.
16. Pawlotsky JM, Dusheiko G, Hatzakis A etal. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 405-415.
17. Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single-topic conference on "Chronic viral hepatitis-strategies to improve effectiveness of screening and treatment". Hepatology 2012; 55: 307-315.
18. Wong DK, Seto WK, Fung J etal. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin. Gastroenterol. Hepatol. 2013; 11: 1004-1010.
19. Manesis EK, Papatheodoridis GV, Tiniakos DG etal. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J. Hepatol. 2011; 55: 61-68.
20. Seto WK, Hui AJ, Wong VW etal. Serum hepatitis B surface antigen levels to guide the cessation of entecavir in hepatitis B e antigen-negative chronic hepatitis B: an interim analysis (abstract). J. Hepatol. 2013; 58 (S1): S315.
21. Jaroszewicz J, Calle Serrano B, Wursthorn K etal. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J. Hepatol. 2010; 52: 514-522.
22. Nguyen T, Thompson AJ, Bowden S etal. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J. Hepatol. 2010; 52: 508-513.
23. Seto WK, Fung J, Yuen MF, Lai CL. Future prevention and treatment of chronic hepatitis B infection. J. Clin. Gastroenterol. 2012; 46: 725-734.
24. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir. Ther. 2006; 11: 909-916.
25. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-791.
26. Seto WK, Lai CL, Fung J etal. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J. Hepatol. 2011; 55: 522-528.
27. Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J. Gastroenterol. Hepatol. 2012; 27: 662-669.
28. Zoutendijk R, Reijnders JG, Brown A etal. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443-451.
29. Lok AS, Trinh H, Carosi G etal. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012; 143: 619-628.
30. Gordon SC, Krastev Z, Horban A etal. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013; 58: 505-513.
31. Tseng TC, Liu CJ, Su TH etal. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-525.